Olema (NASDAQ: OLMA) director granted 27,061 stock options
Olema Pharmaceuticals director Raman Prakash has been granted 27,061 stock options as equity compensation, with an exercise price of $14.59 per share, expiring on April 27, 2036. The options vest based on continuous service, with one portion vesting in full on June 11, 2026, and another in 36 equal monthly installments starting April 28, 2026. This transaction reflects compensation rather than open-market purchases.
FEB 14·MarketBeat▲
Olema Pharmaceuticals CEO Teases Fall OPERA-01 Readout, Q2 KAT6 Data and CFO/COO Exit
Olema Pharmaceuticals CEO Sean Bohen provided updates on the company's pipeline, including an expected Fall readout for the OPERA-01 trial of palazestrant and Q2 2026 data for the KAT6 inhibitor OP-3136. Bohen also addressed the departure of CFO/COO Shane Kovacs, framing it as the company prepares for potential commercialization of palazestrant in the U.S. and seeks ex-U.S. partners. He emphasized palazestrant's potential as a best-in-class oral SERD, citing its pharmacologic attributes and past clinical results.
JAN 7·Investing.com India▲
UBS initiates Olema Pharmaceuticals stock with Buy rating, $45 target By Investing.com
UBS has initiated coverage on Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy rating and a $45 price target, citing the company's unique position with a late-stage Phase III selective estrogen receptor degrader (SERD) and significant upside potential from upcoming catalysts in 2026. The stock has seen extraordinary returns over the past year, driven by anticipation of key data readouts for its palazestrant SERD and a new KAT6 breast cancer drug.
